Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer

  • Li, Xiao-Feng (Department of Comprehensive Medical Oncology, Baotou Cancer Hospital) ;
  • Guo, Xiao-Guang (Department of Surgery, Baotou Cancer Hospital) ;
  • Yang, Yong-Yan (Department of Comprehensive Medical Oncology, Baotou Cancer Hospital) ;
  • Liu, Ai-Yong (Department of Radiotherapy, Baotou Cancer Hospital)
  • Published : 2015.03.04


Background: To explore the relationship between CXCR4, CD133 co-expression and clinicopathological features as well as prognosis of patients with phase II~III colon cancer. Materials and Methods: Forty-nine paraffin-embedded samples of tumor tissue and epithelial tissue adjacent to cancer were collected from patients with colon cancer undergoing radical surgery in Baotou Cancer Hospital from January, 2010 to June, 2011. CXCR4 and CD133 expression was detected using immunohistochemistry and its relationship with clinicopathological features and the 3-year survival rate was analyzed. Results: In the tumor tissue and colonic epithelial tissue adjacent to cancer, the positive expression rates of CXCR4 were respectively 61.2% (30/49) and 8.16% (4/49), while those of CD133 being 36.7% (18/49) and 6.12% (3/49). CXCR4 and CD133 expression in tumor tissue was not related to patient age, gender, primary focal sites, tumor size, TNM staging, histological type, tumor infiltration depth and presence or absence of lymphatic metastasis, but CXCR4 and CD133 co-expression was associated with TNM staging and lymphatic metastasis. The 3-year survival rate of patients with CXCR4 and CD133 co-expression was 27.3% (3/11), and that of the remainderwas 76.3% (29/38), the difference being significant ($X^2=7.0206$, p=0.0081). Conclusions: CXCR4 and CD133 co-expression may be a risk factor for poor prognosis of patients with stage II~III colon cancer.


  1. Bahnassy AA, Fawzy M, El-Wakil M, et al (2014). Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res, [Epub ahead of print].
  2. Chen S, Song X, Chen Z, et al (2013). CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One, 8, 56380.
  3. Chen K, Li Z, Jiang P, et al (2014). Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncol Rep, 32, 755-63.
  4. Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12.
  5. Gupta P, Sharma PK, Mir H, et al (2014). CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget, 5, 10170-9.
  6. Li J, Jiang K, Qiu X, et al (2014). Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep, 47, 33-8.
  7. Liu BL, Liu SJ, Baskys A, et al (2014). Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer. BMC Cancer, 14, 829.
  8. Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al (2014). CXCR4 expression enhances diffuse large B-cell lymphoma dissemination and decreases patient survival. J Pathol, [Epub ahead of print].
  9. Nakata B, Fukunaga S, Noda E, et al (2008). Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology, 74, 69-75.
  10. Oliver JA, Ortiz R, Melguizo C, et al (2014). Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer, 14, 511.
  11. Tan Y, Chen B, Xu W, et al (2014). Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol, 2, 111-5.
  12. Wang N, Luo HJ, Yin GB, et al (2013). Overexpression of HIF- $2{\alpha}$, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma. Clin Dev Immunol, 2013, 589423.
  13. Wu J, Wu X, Liang W, et al (2014). Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a metaanalysis. Tumour Biol, 35, 3709-15.
  14. Wang W, Chen Y, Deng J, et al (2014). The prognostic value of CD133 expression in non-small cell lung cancer: a metaanalysis. Tumour Biol, 35, 9769-75.
  15. Wu H, Qi XW, Yan GN, et al (2014). Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS One, 9, 100168.
  16. Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4.
  17. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.
  18. Xu CZ, Wang PH, Yan XJ, et al (2013). Expression of CXCR4 is associated with progression and invasion in patients with nasal-surface basal cell carcinoma. J Otorhinolaryngol Relat Spec, 75, 332-41.
  19. Yao Q, Sun JG, Ma H, et al (2014). Monitoring microRNAs using a molecular beacon in CD133+/ CD338+ human lung adenocarcinoma-initiating A549 cells. Asian Pac J Cancer Prev, 15, 161-6.
  20. Yang L, Huang XE, Xu L, et al (2013). Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study. Asian Pac J Cancer Prev, 14, 6403-9.
  21. Yu S, Wang X, Liu G, et al (2013). High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. Acta Med Okayama, 67, 369-75.
  22. Zhang Z, Ni C, Chen W, et al (2014). Expression of CXCR4 and breast cancer prognosis: a systematic review and metaanalysis. BMC Cancer, 14, 49.
  23. Zhai JH, Gu WC, Xu XL, et al (2014). Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis. Tumour Biol, [Epub ahead of print].
  24. Zheng NG, Mo SJ, Li JP, et al (2014). Anti-CSC effects in human esophageal squamous cell carcinomas and Eca109/9706 cells induced by nanoliposomal quercetin alone or combined with CD 133 antiserum. Asian Pac J Cancer Prev, 15, 8679-84.

Cited by

  1. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer vol.50, pp.2, 2016,
  2. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis vol.39, pp.6, 2017,
  3. The Effect of Analogues of 1α,25-Dihydroxyvitamin D2 on the Regrowth and Gene Expression of Human Colon Cancer Cells Refractory to 5-Fluorouracil vol.17, pp.6, 2016,
  4. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients vol.97, pp.23, 2018,